Common Stock
Adamas Pharmaceuticals Inc
NASDAQ:ADMS (11/23/2021, 3:18:38 PM)
After market: 8.3 +0.08 (+0.97%)8.22
+0.06 (+0.74%)
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 138 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.
Adamas Pharmaceuticals Inc
1900 Powell St Ste 1000
Emeryville CALIFORNIA 94608
P: 15104503554.0
CEO: Neil F. McFarlane
Employees: 138
Website: https://adamaspharma.com/
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: BayCom Corp (NASDAQ: BCML)...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Rogers Corporation (NYSE: ROG)...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here you can normally see the latest stock twits on ADMS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: